Moonblink, a value-added distributor of wireless and video surveillance solutions, announced today their use of Xirrus’ high-performance wireless Arrays in Angleton Danbury Medical Center in Texas.

Angleton will utilize the Xirrus wireless Arrays for 100 percent wireless coverage throughout the medical center – providing wireless access capable of supporting thousands of users at a time.

High Density of Users Utilizing Both Voice and Data Are No Match for Xirrus’ High-Performance Wireless Arrays

Silicon Valley, April 11, 2012 – Moonblink Communications, a value-added distributor delivering wireless and video surveillance solutions, today announced it worked with PC Care, a value added reseller (VAR) that delivers integrated IT solutions, to provide 100 percent wireless coverage for the Angleton Danbury Medical Center in Texas.

Moonblink and PC Care utilized solutions from Xirrus, a leading provider of high-performance wireless networks, including Xirrus’ XR-4000 Wireless Arrays and the Xirrus Management System (XMS). As a result, Moonblink and PC Care have delivered a wireless network capable of supporting thousands of users running both voice and data applications simultaneously.

“Hospitals are intense environments when it comes to wireless because of the extremely high saturation of devices. Not only computers and tablets, but also VOIP devices for instant communications,” said Daniel Redmond, VP of Sales & Marketing of Moonblink Communications. “When PC Care came to us and said Angleton Danbury Medical Center needed a wireless solution that could support voice badges, wheeled computers, laptops, tablets and more while also providing reliable access for both hospital staff and guests, we knew that Xirrus was the perfect solution.”

After a previous wireless network failed to perform and negatively affected productivity at the hospital, the Angleton Danbury Medical Center contacted PC Care for a solution. The hospital has thousands of employees using a combination of Vocera voice badges for communications, rolling computer stations, as well as laptops and tablets for electronic medical record viewing, creation and updating. And while they needed both voice and data to work at all times for all employees, they needed to prioritize voice traffic.

“The situation with our previous wireless network had become unbearable, and our employees were giving up on using wireless altogether,” said Owen Huett, Director of Information Services at Angleton Danbury Medical Center.

PC Care contacted Moonblink, who they have a long history of working with for their customers’ wireless needs. Due to the extremely high density of users and applications, Moonblink recommended the Xirrus XR-4000 Arrays, each of which have 8 modular access points (operating at either 2.4GHz or 5GHz) and can support up to 1920 users with up to 3.6Gbps. Xirrus did an exhaustive site survey, and determined that they could provide more than enough coverage for the entire 100,000 square foot facility (covering two buildings, each with two floors) with just 25 XR-4000 Wireless Arrays.

“Not only has every hospital employee regained faith in the wireless network, but they now see it as a critical enabler of their productivity,” said Huett. “The combination of Moonblink’s wireless expertise, PC Care’s experience in designing and deploying these networks, and Xirrus’ wireless array and management solutions has transformed the way our staff operates. And even though we have many intensive voice and data apps running concurrently, we still have plenty of bandwidth leftover to provide a reliable wireless network for our guests.”

The Xirrus Management System (XMS) was also deployed, giving the hospital’s IT staff a simple way to monitor and manage the network. Xirrus’ XMS also made it easy to configure multiple SSIDs and VLANs, which they have used to provide three separate access levels: one for internal workers’ data applications, one for internal workers’ Vocera voice traffic, and one for hospital guests.

About Xirrus

Xirrus is the leading provider of high-performance wireless networks. Their array-based solutions perform under the most demanding circumstances—always. With wired-like reliability and superior security allow Xirrus customers to confidently take their business-critical applications and operations mobile. Their solutions are unique in the industry, transforming enterprises and organizations around the world. At a time when everyone expects to connect wirelessly everywhere and business is increasingly done in the cloud, Xirrus wireless solutions are providing a vital strategic business and IT infrastructure advantage in thousands of deployments worldwide. Headquartered in Thousand Oaks, CA, Xirrus is a privately held enterprise designing and manufacturing its products and solutions in the USA.

About Moonblink Communications

Moonblink Communications is a value-added distributor (VAD) with a targeted focus on wireless and video surveillance systems. It is our mission to provide VARs and Integrators the solutions they need to successfully deploy the best wireless systems available for their customers while providing the greatest value. With a targeted wireless technology portfolio from the industry’s leading manufacturers, we provide a complete spectrum of wireless and video surveillance solutions including WiFi, WiMAX, wireless Voice over WiFi, wireless surveillance camera systems, Video Surveillance as a Service (VSaaS), license-free and licensed broadband wireless solutions. For more information, please visit http://www.moonblinkwifi.com or http://cloud.moonblink.com/

Barco recently acquired UK-based JAOtech, a leading designer and manufacturer of medical-grade Smart Terminals for bedside applications. The advanced terminals feature a host of modular options such as barcode scanners, smart card and RFID readers, and partners are provided with specialist software drivers to enable the solution to integrate with the hospital information system (HIS)—providing healthcare staff with secure access to EMRs and vital patient information at the point-of-care.

With this strategic acquisition, Barco broadens its offering with point-of-care solutions.

Kortrijk, Belgium, 03 February 2012 – Healthcare imaging specialist Barco announced today that it has signed an agreement to acquire UK-based JAOtech, a leading manufacturer of patient entertainment and point-of-care terminals for hospitals. The acquisition fits within Barco’s long-term vision of increasing healthcare efficiency and its growth strategy of expanding into multiple healthcare segments. With the JAOtech terminals and associated software, Barco builds a strong position in the fast growing point of care (POC) segment in healthcare.

“Today’s hospitals set extremely high standards when it comes to patient care and comfort. However, a fast growing and ageing population calls for major efforts from hospitals and staff to continue to operate efficiently. For that reason, hospitals need advanced technologies that help improve workflow and hospital productivity”, comments Eric Van Zele, Barco’s President and CEO. “JAOtech’s patient bedside Smart Terminals offer both clinical and entertainment services to help increase hospital efficiency, in addition to giving patients a more comfortable stay.”

JAOtech designs and manufactures medical-grade Smart Terminals for bedside applications. Products include an ergonomic range of mounting solutions and accessories, such as medical keyboards, arms and wall boxes. The advanced terminals are fully customizable and feature a host of modular options such as barcode scanners, smart card and RFID readers. Partners are provided with specialist software drivers to enable the system solution to integrate seamlessly with the hospital information system (HIS) providing healthcare staff with secure access to Electronic Medical Records (EMR) and vital patient information. Patients are presented with an array of education and entertainment tools, such as TV, radio and access to e-mail and the internet.

Piet Candeel, Senior Vice President of Barco and General Manager of Barco’s Healthcare division, adds: “This acquisition fits in our long-term vision of penetrating a wide range of healthcare segments. Today, Barco is market leader in mammography, diagnostic and modality imaging. With the acquisition of JAOtech, we strengthen our position as market leader in healthcare visualization, as the JAOtech terminals enable us to become a leading player in the patient point of care (POC) segment.”

“We are very pleased to become a member of the Barco family”, says Warren Kressinger-Dunn, CEO of JAOtech. “Hospitals around the world are starting to consider the enormous potential of patient bedside entertainment and communication systems. This agreement allows us to capitalize on Barco’s leading position in the healthcare industry, which will definitely help us to expand our reach in the marketplace and become a world player in healthcare.”

JAOtech is headquartered in Surrey, UK and has offices in Taipei City (Taiwan), Amsterdam (The Netherlands), Connecticut (US) and Saarbrücken (Germany). JAOtech employs a staff of approximately 50 people and realized sales of approximately 19 million euro in 2011. The total price paid for the acquisition is below one year sales.

About JAOtech

JAOtech is a multi-award winning market leader providing fully integrated bedside computing and multimedia solutions. JAOtech’s expertise is in the design and manufacturing of a range of bedside Smart Terminals, Smart Healthcare TVs, specialist point-of-care software & associated accessories. Over 55,000 systems have been installed in over 200 hospitals worldwide in partnership with approved technology partners. The terminals provide a core solution for a host of interactive healthcare applications offering secure access to Electronics Medical Records (EMR) and providing triple-play solutions for patient entertainment. JAOtech is dedicated to the betterment of healthcare IT.
About Barco

Barco, a global technology company, designs and develops visualization products for a variety of selected professional markets. Barco has its own facilities for Sales & Marketing, Customer Support, R&D and Manufacturing in Europe, North America and Asia Pacific. Barco (NYSE Euronext Brussels: BAR) is active in more than 90 countries with about 3,500 employees worldwide. Barco posted sales of 897 million euro in 2010.

(NAPLES, FL) — 5th Avenue Acquisitions, a healthcare merger & acquisition firm based in Naples, Florida, recently purchased Serial Ventures, LLC, a business development firm based in New York City.  The move will help 5th Avenue Acquisitions reinforce its position in the healthcare acquisition market, hire new talent and grow internationally.

Serial Ventures was founded in 2005 by Aaron Plaat, an entrepreneur in online ventures, social media applications and online products.  The company provides venture capital to companies that are positioned to go public.

Reagan Rodriguez, CEO/Managing Partner at 5th Avenue Acquisitions said, “We were attracted to Serial Ventures by the vision of the management and the company’s deep market knowledge and expertise. We are delighted to support the future development of Serial Ventures alongside its founder.”

Aaron Plaat, Founder & Managing Director at Serial Ventures, added, “We have found in 5th Avenue Acquisitions a partner with true understanding of our market and a shared vision of the development potential of our business. Collaboration will enable growth and progress for all parties involved through a combination of the online innovations and tools used by Serial Ventures along with the successful application of 5th Avenue Acquisitions’ more standardized business practices.  It’s the perfect blend of traditional business with new innovations.”

Prior to founding 5th Avenue Acquisitions in 2011, Reagan Rodriguez was the Managing Partner of Rodriguez & Swanson, an acquisition firm focused on the dental industry and based in Columbus, Ohio, from 2002 to 2011.

Following the purchase of Serial Ventures, 5th Avenue Acquisitions plans to open 26 new offices throughout the U.S. in the next two years, using partner management at each location.  More information is posted at http://www.5thaavc.com/.

On September 30, 2011, MediServe acquired SpectraSoft, an 18-year-old company that provides scheduling software solutions to the healthcare industry. We’ve had a very close relationship with SpectraSoft for many years. In fact, SpectraSoft’s Founder Steve Petrie worked for MediServe 18 years ago, before he started SpectraSoft. We’re excited to unite our efforts and visions of providing optimal solutions to the healthcare industry.

SpectraSoft brings a valuable contribution to the MediServe Team. Their proven scheduling and documentation software solutions have been implemented in more than 4,500 hospitals and clinics throughout the nation. Their scheduling software is known for its proven ability to simplify the complex scheduling that exists in the healthcare environment.

Chandler, AZ – October 5, 2011 – MediServe announced today its acquisition of SpectraSoft, an 18-year-old company that provides scheduling software solutions to the healthcare industry.

”SpectraSoft is a strong, reputable company that is a proven leader in healthcare related scheduling. More than 4,500 hospitals, clinics, and businesses rely on its products, and we’re excited to unite our efforts and visions of providing optimal solutions to the industry,” said Bill Dyer, President and CEO, MediServe.

The two companies have been technology partners for many years. In fact, SpectraSoft’s Founder and CEO, Steve Petrie, worked for MediServe before starting SpectraSoft. “MediServe knows how to help rehabilitation and respiratory care providers get results through compliance, revenue, and efficiency. Their employees’ expertise and commitment to solving healthcare issues will positively benefit SpectraSoft’s clients,” said Petrie.

The acquisition will merge both companies’ resources, only strengthening the products for current and future clients. SpectraSoft’s team of 18 employees will all stay on board.

SpectraSoft’s scheduling software is known for its proven ability to simplify the complex scheduling that exists in the healthcare environment. The company’s solutions include AppointmentsEverywhere web-based scheduling, AppointmentsPRO series Windows software; DocuPRO rehab documentation, an automated text reminder system and a patient portal. Visit www.spectrasoft.com to see a full list of services.

Financial Highlights
• Total consideration of $130 million, consisting of $77.2 million in cash and 4.1 million shares of common stock
• Positions the Company for stronger future revenue growth and enhanced margins, while achieving meaningful cost synergies
• Projected to increase the Company’s annualized Adjusted EBITDA run-rate  approximately $20 million by year end 2012
• Expected to be modestly accretive to Adjusted Net Income per diluted share in the second half of 2011

Strategic Highlights
• Existing products provide for tighter EHR integration leading to increased physician adoption and Meaningful Use
• Technology pipeline enables new growth opportunities associated with clinical analytics and revenue cycle management
• Leverages core transcription business and provides further differentiation within the HCIT market
• Enables opportunities for greater penetration of the in-house transcription market segment
Operational Highlights
• Provides ownership of speech and Natural Language Understanding technologies
• Facilitates consolidation to a single speech recognition platform
• Accelerates M*Modal’s technology roadmap
• Provides a broader product offering to local and regional transcription partners
• Leverages M*Modal’s cloud-based services to enhance gross margins

Franklin, TN, July 11, 2011 – MedQuist Holdings Inc. (NASDAQ: MEDH), a leading provider of integrated clinical documentation solutions for the U.S. healthcare system, announced the signing of a definitive agreement to acquire M*Modal and its advanced Speech Understanding™ technology for total consideration of $130 million. The transaction is subject to customary closing conditions, including review under the Hart-Scott-Rodino Act, and is expected to close prior to the end of the third quarter of 2011.

M*Modal’s current annualized revenue run rate of $24 million (which includes amounts billed to MedQuist Holdings) is derived from its proprietary cloud-based software solutions that enable healthcare providers to easily convert speech into structured clinical information. This improves physician efficiency, enhances the integration of the physician narrative into electronic health records (EHR), and contributes to the analysis of clinical information for quality and reimbursement requirements.

Vern Davenport, MedQuist Holding’s newly appointed Chairman and Chief Executive Officer, noted, “This transaction combines MedQuist’s strengths of capturing the physician narrative, our large customer base, global presence and deep domain expertise in healthcare with the innovations of M*Modal’s currently available technologies and strong product roadmap. Their scalable cloud-based solutions, Speech Understanding™ platform, strong technology pipeline and a large team of speech and language scientists and engineers complement MedQuist’s clinical workflow solutions.”

Michael Finke, Chief Executive Officer of M*Modal, added, “Given the outstanding strategic fit between us, we are positioned to create a whole new level of clinical documentation workflow and analytics solutions that address some of the healthcare industry’s most pressing issues.  This merger gives M*Modal the immediate resources and access to customers required to accelerate and extend our technology development efforts.”

MedQuist and M*Modal provide advanced speech understanding technologies and services that seamlessly capture the physician narrative, according to Davenport. “We have an opportunity to jointly become a more visible, strategic technology enabler of healthcare organizations as they strive to successfully adopt electronic health records, navigate the move to a value-based healthcare system and derive critical quality and outcomes data from the structured clincial intelligence we create,” he said.

The purchase price, which is subject to customary working capital and cash adjustments, is comprised of $48.4 million in cash paid at closing, $28.8 million in installments paid in cash over the next three years and 4.1 million shares of MedQuist Holdings common stock currently valued at $52.8 million, based on $12.76 per share using the average closing price over the trailing 10 trading days ending immediately prior to the date of signing the definitive agreement. The Company will fund the cash component of the purchase price from available cash. Additionally, the Company expects to incur fees and expenses, including additional restructuring and integration costs associated with this transaction, of approximately $13 million. The Company also expects to accelerate the amortization of approximately $12 million of certain prepaid licensing fees.

The Company obtained consents from the majority of both its senior and subordinated lenders to exclude this acquisition from the appropriate acquisition-related covenants. The Company’s subordinated lenders have agreed to certain additional modifications; principally, reducing the amounts due under existing make-whole provisions, if such debt is exchanged prior to maturity, increasing allowable leverage limits, uncapping the future use of common shares allowed to be used for acquisition and increasing annual amounts available for dividends and stock repurchases up to $25 million, plus available excess cash, as defined.

The Company intends to provide more detailed integration, organizational and branding plans at closing and any updates necessary to its previously issued performance goals for 2011 when it reports second quarter results in mid-August.

Investor Conference Call and Web Simulcast
MedQuist Holdings will host a conference call on July 12, 2011, at 8:00 a.m. CT to discuss the transaction. The number to call for the interactive teleconference is (212) 231-2903. A replay of the conference call will be available through Wednesday, July 19, 2011, by dialing (402) 977-9140 and entering the confirmation number, 21531191.

A live broadcast of MedQuist Holdings quarterly conference call will be available online at the Company’s website, www.medquistholdings.com, under Investor Relations or http://www.videonewswire.com/event.asp?id=80865 on July 12, 2011, beginning at 8:00 a.m. CT. The online replay will follow shortly after the call and continue for one year.

About MedQuist

MedQuist is a leading provider of medical transcription services and a leader in technology-enabled clinical documentation workflow. MedQuist’s enterprise solutions – including mobile voice capture devices, speech recognition, Web-based workflow platforms and a global network of medical editors – help healthcare facilities improve patient care, increase physician satisfaction, and lower operational costs. For more information, please visit www.medquist.com.

About M*Modal

M*Modal, a leader in advanced Speech and Natural Language Understanding technology, transforms narrative medical documentation into structured, encoded information to create meaningful, valuable clinical intelligence that can be shared, analyzed, and used to inform collaborative care.  More than 800 healthcare organizations nationwide utilize M*Modal’s solutions to re-define the role of clinical narrative in improving and promoting quality of care, clinical efficiency, financial performance, and EHR adoption.  For more information, please visit www.mmodal.com.

CHICAGO–(BUSINESS WIRE)– Merge Healthcare Incorporated (NASDAQ:MRGE) (“Merge”) announced today that it commenced a consent solicitation (the “Solicitation”) with respect to proposed amendments to the indenture (the “Indenture”) governing the company’s outstanding $200 million in aggregate principal amount of 11.75% Senior Notes Due 2015 (CUSIP Numbers 589499AB8 and 589499AA0 and ISIN Number USU58948AA53). The proposed amendments would enable Merge to undertake an offering of an additional amount of notes under the Indenture in an aggregate principal amount not to exceed $52.0 million (the “Additional Note Offering”).

The proceeds of the Additional Note Offering will be used solely to repurchase all of Merge’s outstanding Series A Preferred Stock (current accrued liquidation preference of approximately $49 million) and to pay consent fees, legal, printing and accounting costs and other expenses related to these proposed transactions. The holders of the Preferred Stock have agreed to certain amendments to the terms of the Series A Preferred Stock that will permit this redemption without the payment of otherwise-required redemption premiums of approximately $6 million. The Company believes that it is in the best interests of the Company and its stockholders to redeem the Series A Preferred Stock at this time, given the accruing 15% coupon on the Series A Preferred Stock (as compared to the 11.75% coupon on the Senior Notes) and the uncertainty as to whether market conditions would permit a similar additional note offering and preferred stock redemption in the future. While the Company will incur additional cash expense in 2011 and 2012 as a result of these transactions, the Company believes that a less complicated capital structure will facilitate better investor awareness of its operations and financial status.

None of the Company’s proceeds from the Additional Note Offering will be used to finance the Company’s recently announced proposed acquisition of Ophthalmic Imaging Systems, Inc. (“OIS”). In that transaction, the Company will exchange its common stock for all of the outstanding common stock of OIS. The Company’s out-of-pocket expenses related to the OIS transaction will be paid from the Company’s available cash. Because the OIS acquisition is unrelated, the closings of the Solicitation, the Additional Note Offering and the Series A Preferred Stock redemption (which are expected to occur in mid-June) will be independent from, and not contingent upon, the OIS closing (which is not expected to occur before July). Likewise, the OIS closing is not contingent on the closing of these financing transactions.

The record date to determine holders of the notes entitled to consent is June 3, 2011. The Solicitation will expire at 5:00 p.m., New York City time, on June 14, 2011, unless extended (the “Expiration Date”). As part of the Solicitation, Merge will make a cash payment (the “Consent Payment”) of $10.00 per $1,000 in principal amount of notes to each holder who has validly delivered a duly executed consent (the “Consent”) on or prior to the Expiration Date in accordance with the procedures described in the Consent Solicitation Statement (the “Solicitation Statement”). There are no revocation rights applicable to the Consent and, once delivered, Consents may not be revoked. Merge’s obligation to make the Consent Payment is contingent, among other things, upon the conditions described in the Solicitation Statement, including receipt of the Requisite Consents (as defined in the Solicitation Statement) on or prior to the Expiration Date and the consummation of the Additional Note Offering. The Consent Payment will be paid promptly following the satisfaction of the conditions outlined in the Solicitation Statement, including the consummation of the Additional Note Offering.

Holders of the notes may obtain a copy of the Solicitation Statement and related material from the information agent, D.F. King & Co., Inc., at (800) 758-5880 or (212) 269-5550 for banks and brokers.

Morgan Stanley & Co. LLC is the solicitation agent for the consent solicitation. Questions regarding the consent solicitation may be directed to the solicitation agent at (800) 624-1808 or (212) 761-1057.

Merge Healthcare Incorporated is a leading provider of enterprise imaging and interoperability solutions. Merge Healthcare solutions facilitate the sharing of images to create a more effective and efficient electronic healthcare experience for patients and physicians. Merge Healthcare provides enterprise imaging solutions for radiology, cardiology and orthopaedics; a suite of products for clinical trials; software for financial and pre-surgical management, and applications that fuel the largest modality vendors in the world. Merge Healthcare’s products have been used by healthcare providers, vendors and researchers worldwide to improve patient care for more than 20 years. Additional information can be found at www.merge.com.

The acquisition of Lexi-Comp will enable Wolters Kluwer Health to further strengthen its leading position in the clinical decision support and point-of-care information segments and to provide customers with even more robust drug information and clinical content offerings for both hospital pharmacies and overall hospital enterprises. It will also enable pharmacist, physician and nurse customers to use an extended suite of mobile capabilities and online platforms, making access to critical medical information more convenient than ever before.

Acquisition Strengthens Wolters Kluwer Leading Position in the Clinical Solutions Space

Philadelphia, PA – (April 27, 2011) – Wolters Kluwer Health, a leading provider of information and business intelligence for professionals, students and institutions in medicine, nursing, allied health and pharmacy, today announced that it has entered into an agreement to acquire Lexi-Comp, Inc., a leading provider of drug information and clinical content for pharmacists and clinicians. The acquisition is the latest in a series of strategic acquisitions Wolters Kluwer Health has made in its Clinical Solutions business as part of the company’s strong focus on serving the point-of-care segment.

“Wolters Kluwer Health has focused heavily on building a robust suite of clinical decision support solutions for point-of-care use by healthcare professionals, and our acquisition of Lexi-Comp is very much aligned with this strategy,” said Arvind Subramanian, President & CEO, Wolters Kluwer Health Clinical Solutions. “Like Wolters Kluwer Health’s current Clinical Solutions businesses, Lexi-Comp is a leader in providing quality drug information and clinical content designed to help pharmacists and other healthcare professionals make informed and efficient clinical judgments and decisions to improve the quality of care they can provide for their patients. With this acquisition, over 500,000 pharmacists and clinicians in 149 countries will have access to Wolters Kluwer Health Clinical Solutions. Following completion of the acquisition, our combined businesses will be well-positioned to provide a robust portfolio of clinical decision support solutions for professional customers across the healthcare continuum.”

Lexi-Comp provides drug information and medical reference content to more than 1,500 hospitals internationally, and publishes drug monographs covering more than 1,700 products.   Lexi-Comp’s clinical information is available to pharmacists and other healthcare professionals online and on a variety of popular mobile devices, as well as through integrated health information systems. To support and supplement effective clinician-patient interactions, Lexi-Comp also provides patient medication leaflets in 19 languages. The company is headquartered near Cleveland, Ohio and has approximately 150 employees.

The two companies have a long-standing relationship through Wolters Kluwer Health’s UpToDate business. UpToDate offers an electronic clinical information resource via the internet and mobile devices, with one of the world’s largest online clinical information communities including more than 4,400 expert clinicians who function as authors, editors and peer reviewers and over 400,000 users who provide questions and feedback.  UpToDate covers more than 8,500 topics in 17 medical specialty areas, with integrated Lexi-Comp drug information and clinical content offered through the UpToDate platform.

The acquisition of Lexi-Comp will enable Wolters Kluwer Health to further strengthen its leading position in the clinical decision support and point-of-care information segments and to provide customers with even more robust drug information and clinical content offerings for both hospital pharmacies and overall hospital enterprises. It will also enable pharmacist, physician and nurse customers to use an extended suite of mobile capabilities and online platforms, making access to critical medical information more convenient than ever before.

The transaction is subject to customary closing conditions, including the receipt of required regulatory approvals. Terms of the acquisition were not disclosed. For more information on Wolters Kluwer Health, visit www.wolterskluwerhealth.com. For more information on Lexi-Comp, visit www.lexi.com.

About Wolters Kluwer Health
Wolters Kluwer Health (Philadelphia, PA) is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries and territories worldwide, Wolters Kluwer Health’s customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools, journals and textbooks, such as Lippincott Williams & Wilkins; and electronic information providers, such as Ovid^®, UpToDate^®, Medi-Span^®, Facts & Comparisons^®, Pharmacy OneSource^® and ProVation^® Medical.

Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer has 2010 annual revenues of €3.5 billion ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America.

ACS, A Xerox Company, has acquired CredenceHealth, Inc. – a provider of software that captures and analyzes patient data – helping healthcare providers improve patient care and meet meaningful use requirements.

Coupling CredenceHealth’s clinical surveillance tools with ACS’ core suite of managed care solutions, the company will offer MIDAS+Live, a cloud solution that integrates with a hospital’s Electronic Medical Record system and actively monitors patient data, providing caregivers real-time information.

ACS, A Xerox Company, to Acquire CredenceHealth, Inc.; Adds Cloud-Based Solution to Help Healthcare Providers Enhance Quality of Care

DALLAS, March 21, 2011 – Affiliated Computer Services, Inc. (ACS), A Xerox Company (NYSE: XRX), today announced a definitive agreement to acquire CredenceHealth, Inc., creating a simple way for healthcare providers to use patient information to predict and prevent complications.

Nashville, Tenn.-based CredenceHealth provides software that captures and analyzes patient data to assist hospitals, health plans, and providers improve quality of care and compliance with meaningful use regulations.

By integrating CredenceHealth’s clinical surveillance tools with ACS’ core suite of managed care solutions under the Midas software brand, ACS will now offer a cloud-based solution that actively monitors patient data – original diagnosis, laboratory and radiology reports, medications, vital signs, etc. This data is   accessible to hospital staff from any Internet browser using a secure password-protected system.

The new solution, named Midas+ Live, works with a hospital’s Electronic Medical Record (EMR) system, and alerts caregivers when any of thousands of possible changes in a patient’s condition happen simultaneously – such as an increase in temperature or low blood pressure, combined with various lab and radiology results. This information can then be used to inform the caregiver prior to a decline in the patient’s condition.

“Through our advanced technology that analyzes the insights found inside the massive amounts of information regarding a patient’s condition, we’re giving healthcare providers real-time relevant knowledge so they can better focus on giving patients the care they need,” said Tom Simas, managing director for ACS’ Midas+ solutions.

The CredenceHealth software-as-a-service offering is certified by the Office of the National Coordinator as a clinical quality measures reporting module for meaningful use. Therefore, providers using Midas+ Live will be eligible for stimulus dollars from the HITECH and American Recovery and Reinvestment Act.

“We have experienced great gains in quality outcomes and efficiencies since adding CredenceHealth’s tools to our organization. Our colleagues benefit from having this information and intelligence at their fingertips,” said Scott Raynes, president and CEO, NorthCrest Medical Center in Springfield, Tenn. “The addition of CredenceHealth to our existing ACS Midas+ processes and products creates a powerful combination, helping us accomplish all of the new regulatory requirements, freeing us to deliver even better care to our patients.”

All CredenceHealth products and services will be integrated into Midas+ solutions, which help to improve staff efficiency, enhance patient safety and increase hospital profitability. CredenceHealth’s management team and employees will join ACS. Justin Lanning, CEO, CredenceHealth, will serve as vice president of business development, ACS Midas+.

About Xerox

Xerox Corporation is a $22 billion leading global enterprise for business process and document management. Through its broad portfolio of technology and services, Xerox provides the essential back-office support that clears the way for clients to focus on what they do best: their real business. Headquartered in Norwalk, Conn., Xerox provides leading-edge document technology, services, software and genuine Xerox supplies for graphic communication andoffice printing environments of any size. Through ACS, A Xerox Company, which Xerox acquired in February 2010, Xerox also offers extensive business process outsourcing and IT outsourcing services, including data processing, HR benefits management, finance support, and customer relationship management services for commercial and government organizations worldwide. The 136,000 people of Xerox serve clients in more than 160 countries. For more information, visit http://www.xerox.com, http://news.xerox.com, http://www.realbusiness.com orhttp://www.acs-inc.com. For investor information, visit http://www.xerox.com/investor.

About CredenceHealth, Inc.
CredenceHealth automates Core and eMeasure compliance and identifies emerging complications via a unique Clinical Intelligence Engine. CredenceHealth web-based infrastructure delivers meaningful and actionable clinical surveillance in real-time – while patients are still in the hospital – utilizing evidence-based medical research and best practice standards (e.g., CMS, HITSP, CDC, NSQIP, and other published standards). http://www.credencehealth.md